Adenosine A2B Receptor Antagonism Interferes with TGF-β Cellular Signaling Through SMAD2/-3 and p65-Nf-κB in Podocytes and Protects from Phenotypical Transformation in Experimental Diabetic Glomerulopathy
Cells · 2025
DOI: 10.3390/cells14120890 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Ignacio Arias und 9 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Pathology Laboratory, Institute of Biochemistry and Microbiology, Science Faculty, Universidad Austral de Chile, Valdivia 5110566, Chile. Hauptthemen laut MEDLINE: Podocytes, Diabetic Nephropathies, Signal Transduction, Transforming Growth Factor beta. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo, ANID-Chile, Millennium Science Initiative Program.
Abstract (Originalsprache)
Studies have emphasized alleviating fibrogenesis through interference with adenosine signaling in experimental diabetic nephropathy. We found that the in vivo antagonism of the adenosine A2B receptor (A2BAR) using MRS1754 in diabetic rats impedes the diabetes-induced glomerular expression of the mesenchymal-like transformation markers Snail and α-SMA, while the loss of the epithelial podocyte-specific proteins nephrin and ZO-1 was prevented. Furthermore, the production of MCP-1, CCL3, TGF-β, and the transcript levels of inflammatory mediators was reduced by A2BAR antagonism. Using human podocytes in vitro, we demonstrated that A2BAR antagonism affected the TGF-β-induced activation of SMAD2/-3, as evidenced by the attenuated phosphorylation of SMAD2/-3 and decreased SMAD3 occupancy at target gene promoters following the MRS1754 treatment. Moreover, the non-canonical activation of p65-NF-κB, the primary inflammatory signaling pathway downstream of TGF-β, and the expression of Snail were also reduced by MRS1754. We conclude that an A2BAR blockade interferes with the pathogenic TGF-β signaling cascade responsible for the phenotypical transformation of podocytes, thereby alleviating diabetic glomerulopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Pathology Laboratory, Institute of Biochemistry and Microbiology, Science Faculty, Universidad Austral de Chile, Valdivia 5110566, Chile.
- Tumor Biology Laboratory, Institute of Biochemistry and Microbiology, Science Faculty, Universidad Austral de Chile, Valdivia 5110566, Chile.
- Millennium Institute on Immunology and Immunotherapy, Universidad Austral de Chile, Valdivia 5110566, Chile.
- Escuela de Medicina Veterinaria, Facultad de Medicina Veterinaria y Recursos Naturales, Sede Talca, Universidad Santo Tomás, Talca 3473620, Chile.
ORCID-Profile: Pablo Mendoza-Soto, Claudio Cappelli, Angelo Torres-Arévalo
Förderung
- Agencia Nacional de Investigación y Desarrollo
- ANID-Chile
- Millennium Science Initiative Program
Zitieren
APA
Arias, I., Jara, C., Mendoza-Soto, P., Nahuelpán, Y., Cappelli, C., Oyarzún, C., Carrillo-Beltrán, D., Quezada-Monrás, C., Torres-Arévalo, A., & San Martín, R. (2025). Adenosine A2B Receptor Antagonism Interferes with TGF-β Cellular Signaling Through SMAD2/-3 and p65-Nf-κB in Podocytes and Protects from Phenotypical Transformation in Experimental Diabetic Glomerulopathy. Cells. https://doi.org/10.3390/cells14120890
Vancouver
Arias I, Jara C, Mendoza-Soto P, Nahuelpán Y, Cappelli C, Oyarzún C, et al. Adenosine A2B Receptor Antagonism Interferes with TGF-β Cellular Signaling Through SMAD2/-3 and p65-Nf-κB in Podocytes and Protects from Phenotypical Transformation in Experimental Diabetic Glomerulopathy. Cells. 2025. doi:10.3390/cells14120890
BibTeX
@article{Arias2025,
author = {Arias, Ignacio and Jara, Claudia and Mendoza-Soto, Pablo and Nahuelpán, Yessica and Cappelli, Claudio and Oyarzún, Carlos and Carrillo-Beltrán, Diego and Quezada-Monrás, Claudia and Torres-Arévalo, Angelo and San Martín, Rody},
title = {Adenosine A2B Receptor Antagonism Interferes with TGF-β Cellular Signaling Through SMAD2/-3 and p65-Nf-κB in Podocytes and Protects from Phenotypical Transformation in Experimental Diabetic Glomerulopathy},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14120890}
}
EUVIMED